US EditionFunding in obesity, oncology and immunology: 2024 sales data show where science is paying off
Summary by Research & Development World
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Funding in obesity, oncology and immunology: 2024 sales data show where science is paying off
Follow the money and you’ll spot the biology that paid off in 2024. PD-1 immunotherapy kept oncology on top, with Keytruda ringing up $29.5 billion in revenue. In obesity and diabetes, the top five GLP-1/GIP incretins (Ozempic, Mounjaro, Wegovy, Rybelsus and Trulicity) pulled in **$46.1 billion**, up a remarkable **37.8 %** year over year. And… The post Funding flows to obesity, oncology and immunology: 2024 sales data show where science is pa…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
